Regeneron’s 10933 and 10987 Antibodies, the REGN-COV2 Study

REGN-COV-2 is testing a combination of two antibodies called REGN10933 and REGN10987 to see whether they are able to prevent acquisition of SARS-CoV-2. This study will enroll approximately 2,000 adults in the United States who are living in the same household as a person who has recently tested positive for SARS-CoV-2. This will include about 1,700 participants who test SARS-CoV-2 negative at enrollment and about 300 participants who have a positive SARS-CoV-2 test result but do not have any COVID-19 symptoms.

The REGN10933 and REGN10987 antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The antibodies were made in a lab by the pharmaceutical company Regeneron. REGN10933 and REGN10987 cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.

Learn more about the Regeneron monoclonal antibody clinical study and the antibodies used:

• Visit www.regeneron.com/covid19 or ClinicalTrials.gov> - NCT04452318 for additional information about the study.
• Press Release: Regeneron's Regn-Cov2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients, Sept. 29, 2020
• Webcast: Regeneron COVID-19 Program Update, Sept. 29, 2020
• Volunteer Registry